Dudediligence.

Neuphoria Therapeutics Inc

NEUPNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$662,715Dec ’24$15.0MMar ’25−$13,267Jun ’25
Net income, by quarter
−$804,787Sep ’24−$1.9MDec ’24$11.3MMar ’25−$8.9MJun ’25−$9.9MSep ’25$1.9MDec ’25−$505,063Mar ’26−$4.9MJun ’26
Fiscal years, by the month each ended
LineJun 2022Jun 2023Jun 2024Jun 2025Jun 2026
Revenuenone on filenone on filenone on file$15.6M$1.2M
Operating incomenone on file−$22.0M−$17.9M−$1.1M−$16.5M
Net incomenone on file−$21.4M−$15.5M−$369,632−$13.5M
Operating cash flownone on file−$14.6M−$14.7M$77,229−$12.4M
Cash$23.2M$12.1M$12.6M$14.2M$19.9M
Shares outstandingnone on file1.47B1.1M2.0M5.4M